Q1FY27 Results: Standalone Revenue Down 41%, Consolidated Net Loss
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Board approved Q1FY27 results (quarter ended June 30, 2026). Standalone revenue fell 41% YoY to Rs 55.5 cr vs Rs 94.4 cr due to base effect from large Q1FY26 institutional order. Standalone PAT dropped to Rs 3.7 cr from Rs 10 cr. Consolidated revenue fell 19% to Rs 93.7 cr; net loss widened to Rs 3.6 cr from Rs 0.9 cr, driven by Innoxel losses. EBITDA margin compressed to 9.1%. Subsidiaries grew strongly. Hemang Shah reappointed as Executive Director for 5 years. AGM on September 19, 2026.
Weak Q1 on standalone base effect; consolidated loss and margin compression may weigh on sentiment, though FY27 guidance is reaffirmed.